Status:
NOT_YET_RECRUITING
Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Lead Sponsor:
Methodist Health System
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.
Detailed Description
The study mainly focused for the following objectives: To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely ...
Eligibility Criteria
Inclusion
- Age 18-45
- Body mass index(BMI) \> 30
- Diagnosis of PCOS
- Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone
Exclusion
- Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
- Letrozole, clomiphene citrate, FSH therapy
- Androgen receptor blockers
- 5α reductase inhibitors
- Insulin
- Hysterectomy
- Endometrial ablation
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT06222437
Start Date
January 1 2025
End Date
January 1 2026
Last Update
March 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Institute at Methodist Health System
Dallas, Texas, United States, 75203